Franklin Genomic Advancements ETF (BATS:HELX) Short Interest Down 74.2% in July

Franklin Genomic Advancements ETF (BATS:HELX) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 4,118 shares, a decrease of 74.2% from the June 30th total of 15,981 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average trading volume of 3,276 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Investors Weigh In On Franklin Genomic Advancements ETF

Several institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. raised its holdings in Franklin Genomic Advancements ETF by 19.1% during the 2nd quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after buying an additional 502 shares during the period. LPL Financial LLC boosted its stake in shares of Franklin Genomic Advancements ETF by 22.4% during the 4th quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after purchasing an additional 2,037 shares during the period. Raymond James Financial Inc. bought a new position in Franklin Genomic Advancements ETF during the 2nd quarter valued at about $42,000. Finally, Kestra Advisory Services LLC purchased a new stake in Franklin Genomic Advancements ETF in the 4th quarter worth about $39,000.

Franklin Genomic Advancements ETF Price Performance

Franklin Genomic Advancements ETF stock opened at $38.85 on Monday. Franklin Genomic Advancements ETF has a 52-week low of $27.54 and a 52-week high of $41.30. The firm’s fifty day moving average is $37.20 and its 200 day moving average is $35.43. The company has a market cap of $15.54 million, a price-to-earnings ratio of 26.71 and a beta of 1.05.

Franklin Genomic Advancements ETF Company Profile

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.